Are TCAs Generally Safe to Prescribe?
Tricyclic antidepressants carry significant cardiovascular risks and should be prescribed with caution, particularly in older adults and those with cardiac risk factors, as they increase the risk of cardiac arrest, serious arrhythmias, and death in overdose.
Cardiovascular Risks at Therapeutic Doses
TCAs pose substantial cardiac hazards even when used at recommended doses. Treatment with TCAs increases the risk of cardiac arrest by 69% (OR = 1.69) compared to non-users, with the mean age of affected patients being 67 years 1. The mechanism involves:
- Delayed AV-node conduction resulting in AV block
- QT-interval prolongation predisposing to Torsades de Pointes
- Dose-dependent increases in serious cardiac events 1
A 2024 systematic review confirmed that amitriptyline, nortriptyline, and lofepramine are associated with greater risk of in-use cardiotoxicity 2. The evidence shows TCAs can be cardiotoxic even at therapeutic levels, with plasma levels too variable to define a truly safe therapeutic range 3.
Serious Adverse Events
Beyond cardiac risks, TCAs increase the odds of serious adverse events by 2.78-fold (OR 2.78; 95% CI 2.18-3.55) compared to placebo 4. This represents a clinically significant harm profile that must be weighed against any potential benefits.
Overdose Toxicity
TCAs remain highly dangerous in overdose, with fatal toxicity indices in the order of 10¹-10² for most agents 2. Desipramine appears most lethal in overdose, while lofepramine has the lowest risk 2. However, recent data from England and Wales (2016-2020) show declining TCA poisoning mortality despite increased prescribing, likely because low-dose amitriptyline formulations (10 mg) now dominate prescribing patterns 5.
High-Risk Populations Requiring Extra Caution
Patients over 65 years old warrant particular concern, as 22.5% of TCA prescriptions go to this age group 6, yet they experience higher rates of cardiac arrest 1. The guideline explicitly recommends:
- Baseline ECG if cardiac risk factors present
- Monitoring for bradycardia, T-wave changes, and AV block 1
- Avoiding concomitant use with anti-arrhythmic drugs 1
Clinical Decision Algorithm
When considering TCA prescription:
- Assess cardiac risk factors - ischemic heart disease, arrhythmia history, age >65, concomitant QT-prolonging medications
- Obtain baseline ECG if any cardiac risk factors present 1
- Consider safer alternatives first - SNRIs show no association with cardiac arrest 1 and have fewer adverse events than TCAs 7
- If TCA necessary, choose lofepramine for lowest overdose risk 2, or low-dose amitriptyline (10 mg) formulations 5
- Monitor with follow-up ECGs in at-risk patients 1
- Assess suicide risk given overdose lethality
Important Caveats
The evidence base has critical limitations. All efficacy data come from trials lasting only 12 weeks maximum, meaning long-term safety and effects on quality of life remain unknown 4. The certainty of evidence is very low to low due to high risk of bias 4.
Despite showing a 3.77-point reduction on the Hamilton Depression Rating Scale (barely exceeding the 3-point minimal important difference), this modest benefit must be weighed against the 2.78-fold increase in serious adverse events 4.
The continued use of TCAs should be minimized given their undoubted toxicity in overdose and proven toxicity in normal clinical use 2. They are no longer NICE-recommended first-line treatment for depression 5, and safer alternatives exist for most indications.